FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2536452417> ?p ?o ?g. }

• W2536452417 endingPage "2081" @default.
• W2536452417 startingPage "2074" @default.
• W2536452417 abstract "To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).In this retrospective uncontrolled observational multicenter study, off-label rituximab-treated patients with MS were identified through the Swedish MS register. Outcome data were collected from the MS register and medical charts. Adverse events (AEs) grades 2-5 according to the Common Terminology Criteria for Adverse Events were recorded.A total of 822 rituximab-treated patients with MS were identified: 557 relapsing-remitting MS (RRMS), 198 secondary progressive MS (SPMS), and 67 primary progressive MS (PPMS). At baseline, 26.2% had contrast-enhancing lesions (CELs). Patients were treated with 500 or 1,000 mg rituximab IV every 6-12 months, during a mean 21.8 (SD 14.3) months. During treatment, the annualized relapse rates were 0.044 (RRMS), 0.038 (SPMS), and 0.015 (PPMS), and 4.6% of patients displayed CELs. Median Expanded Disability Status Scale remained unchanged in RRMS (p = 0.42) and increased by 0.5 and 1.0 in SPMS and PPMS, respectively (p = 0.10 and 0.25). Infusion-related AEs occurred during 7.8% of infusions and most were mild. A total of 89 AEs grades ≥2 (of which 76 infections) were recorded in 72 patients. No case of progressive multifocal leukoencephalopathy was detected.This is the largest cohort of patients with MS treated with rituximab reported so far. The safety, clinical, and MRI findings in this heterogeneous real-world cohort treated with different doses of rituximab were similar to those reported in previous randomized controlled trials on B-cell depletion therapy in MS.This study provides Class IV evidence that for patients with MS, rituximab is safe and effective." @default.
• W2536452417 created "2016-10-28" @default.
• W2536452417 creator A5000664165 @default.
• W2536452417 creator A5012945005 @default.
• W2536452417 creator A5013980439 @default.
• W2536452417 creator A5031138774 @default.
• W2536452417 creator A5035345316 @default.
• W2536452417 creator A5041446091 @default.
• W2536452417 creator A5050988193 @default.
• W2536452417 creator A5057206152 @default.
• W2536452417 creator A5058748370 @default.
• W2536452417 creator A5077631565 @default.
• W2536452417 creator A5077965167 @default.
• W2536452417 creator A5081657251 @default.
• W2536452417 creator A5085063312 @default.
• W2536452417 creator A5086810017 @default.
• W2536452417 date "2016-10-19" @default.
• W2536452417 modified "2023-10-14" @default.
• W2536452417 title "Rituximab in multiple sclerosis" @default.
• W2536452417 cites W1553818824 @default.
• W2536452417 cites W1821735551 @default.
• W2536452417 cites W2048324178 @default.
• W2536452417 cites W2093648460 @default.
• W2536452417 cites W2104188690 @default.
• W2536452417 cites W2105159132 @default.
• W2536452417 cites W2105167551 @default.
• W2536452417 cites W2107008240 @default.
• W2536452417 cites W2114360739 @default.
• W2536452417 cites W2117941205 @default.
• W2536452417 cites W2124231203 @default.
• W2536452417 cites W2127293899 @default.
• W2536452417 cites W2128600935 @default.
• W2536452417 cites W2141111992 @default.
• W2536452417 cites W2142577589 @default.
• W2536452417 cites W2143771994 @default.
• W2536452417 cites W2178334732 @default.
• W2536452417 cites W2282058593 @default.
• W2536452417 cites W2313484897 @default.
• W2536452417 cites W2509277703 @default.
• W2536452417 doi "https://doi.org/10.1212/wnl.0000000000003331" @default.
• W2536452417 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5109942" @default.
• W2536452417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27760868" @default.
• W2536452417 hasPublicationYear "2016" @default.
• W2536452417 type Work @default.
• W2536452417 sameAs 2536452417 @default.
• W2536452417 citedByCount "253" @default.
• W2536452417 countsByYear W25364524172016 @default.
• W2536452417 countsByYear W25364524172017 @default.
• W2536452417 countsByYear W25364524172018 @default.
• W2536452417 countsByYear W25364524172019 @default.
• W2536452417 countsByYear W25364524172020 @default.
• W2536452417 countsByYear W25364524172021 @default.
• W2536452417 countsByYear W25364524172022 @default.
• W2536452417 countsByYear W25364524172023 @default.
• W2536452417 crossrefType "journal-article" @default.
• W2536452417 hasAuthorship W2536452417A5000664165 @default.
• W2536452417 hasAuthorship W2536452417A5012945005 @default.
• W2536452417 hasAuthorship W2536452417A5013980439 @default.
• W2536452417 hasAuthorship W2536452417A5031138774 @default.
• W2536452417 hasAuthorship W2536452417A5035345316 @default.
• W2536452417 hasAuthorship W2536452417A5041446091 @default.
• W2536452417 hasAuthorship W2536452417A5050988193 @default.
• W2536452417 hasAuthorship W2536452417A5057206152 @default.
• W2536452417 hasAuthorship W2536452417A5058748370 @default.
• W2536452417 hasAuthorship W2536452417A5077631565 @default.
• W2536452417 hasAuthorship W2536452417A5077965167 @default.
• W2536452417 hasAuthorship W2536452417A5081657251 @default.
• W2536452417 hasAuthorship W2536452417A5085063312 @default.
• W2536452417 hasAuthorship W2536452417A5086810017 @default.
• W2536452417 hasBestOaLocation W25364524171 @default.
• W2536452417 hasConcept C126322002 @default.
• W2536452417 hasConcept C197934379 @default.
• W2536452417 hasConcept C203014093 @default.
• W2536452417 hasConcept C2777793932 @default.
• W2536452417 hasConcept C2778375690 @default.
• W2536452417 hasConcept C2779338263 @default.
• W2536452417 hasConcept C2780640218 @default.
• W2536452417 hasConcept C2780644213 @default.
• W2536452417 hasConcept C2780653079 @default.
• W2536452417 hasConcept C2780892749 @default.
• W2536452417 hasConcept C2781004633 @default.
• W2536452417 hasConcept C71924100 @default.
• W2536452417 hasConcept C72563966 @default.
• W2536452417 hasConcept C90924648 @default.
• W2536452417 hasConceptScore W2536452417C126322002 @default.
• W2536452417 hasConceptScore W2536452417C197934379 @default.
• W2536452417 hasConceptScore W2536452417C203014093 @default.
• W2536452417 hasConceptScore W2536452417C2777793932 @default.
• W2536452417 hasConceptScore W2536452417C2778375690 @default.
• W2536452417 hasConceptScore W2536452417C2779338263 @default.
• W2536452417 hasConceptScore W2536452417C2780640218 @default.
• W2536452417 hasConceptScore W2536452417C2780644213 @default.
• W2536452417 hasConceptScore W2536452417C2780653079 @default.
• W2536452417 hasConceptScore W2536452417C2780892749 @default.
• W2536452417 hasConceptScore W2536452417C2781004633 @default.
• W2536452417 hasConceptScore W2536452417C71924100 @default.
• W2536452417 hasConceptScore W2536452417C72563966 @default.
• W2536452417 hasConceptScore W2536452417C90924648 @default.

• next